Otano, Itziar http://orcid.org/0000-0002-1433-1711
Ucero, Alvaro C. http://orcid.org/0000-0002-5575-0808
Zugazagoitia, Jon
Paz-Ares, Luis
Article History
Accepted: 29 November 2022
First Online: 13 January 2023
Competing interests
: I.O. declares no competing interests. A.C.U. has received honoraria for participation at meetings from AstraZeneca Spain. J.Z. has received honoraria for participation at meetings from AstraZeneca Spain, Bristol Myers Squibb/Celgene, Guardant Health, NanoString Technologies, Pfizer and Roche/Genentech; speakers’ bureau fees from AstraZeneca, Bristol Myers Squibb/Celgene, Guardant Health, MSD Oncology, NanoString Technologies, Pfizer, and Roche; research funding (via his institution) from AstraZeneca and Roche/Genentech; travel and accommodation expenses from Bristol Myers Squibb/Celgene; and declares consultancy or advisory roles with AstraZeneca, Bristol Myers Squibb/Celgene, Guardant Health, Novartis and Pfizer. L.P.-A. has leadership interest (board member) in ALTUM Sequencing and Genomica; has received honoraria for participation at meetings from Amgen Sanofi, AstraZeneca Spain, Bayer, Blueprint Medicines, Bristol Myers Squibb/Celgene, Daiichi Sankyo, Ipsen, Lilly, Merck Serono, Mirati Therapeutics, Novartis, Pfizer, PharmaMar, Roche/Genentech, Servier and Takeda; speakers’ bureau fees from AstraZeneca, Bristol Myers Squibb, Merck Serono, MSD Oncology, Pfizer and Roche/Genentech; research funding (via his institution) from AstraZeneca, Bristol Myers Squibb, Kura Oncology, MSD, Pfizer and PharmaMar; and travel and accommodation expenses from AstraZeneca, Bristol Myers Squibb/Celgene, MSD, Pfizer Roche/Genentech and Takeda. L.P-A. also declares other relationships with Amgen, Ipsen, Merck, Novartis, Pfizer, Roche, Sanofi and Servier (as sponsors of clinical trials).